4:01 PM ET
10-Q
Financial Results
Hemab Therapeutics Holdings Q3 2026 Results: Net Loss of $27.3M, Loss Widens
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for bleeding disorders, including its lead candidate sutacimig currently in Phase 3 trials. The company remains pre-revenue, incurring significant operating losses as it advances its clinical pipeline, and anticipates the need for substantial additional funding to support its research and development programs.
- Key figure
- Net loss $27.3M